Overview

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott